Reviva Pharmaceuticals Holdings, Inc. (RVPH) Dividend History

Reviva Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. Founded to leverage its expertise in drug discovery and development, Reviva aims to address unmet medical needs through innovative solutions. The company's pipeline includes candidates targeting conditions such as depression, anxiety, and other neuropsychiatric disorders.

10080 N Wolfe Road, Cupertino, CA, 95014
Phone: (408) 501-8881
Website: https://www.revivapharma.com

Dividend History

Reviva Pharmaceuticals Holdings, Inc. currently does not pay dividends

Company News

Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight

The schizophrenia market is expected to grow significantly by 2034, driven by rising disease prevalence, expanding approved therapies, and the anticipated launch of new treatments such as Olanzapine LAI, Iclepertin, Ulotaront, and Brilaroxazine.

GlobeNewswire Inc.

Featured Companies: NERV
Reviva to Participate in the 2025 BIO CEO & Investor Conference

Reviva Pharmaceuticals Holdings, Inc. (RVPH), a late-stage pharmaceutical company, announced that its Founder, President, and CEO will participate in a panel discussion at the 2025 BIO CEO & Investor Conference, focusing on tackling mental health through new targets and endpoints progress.

GlobeNewswire Inc.
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The 5-HT2 agonist pipeline is robust, with over 20 pharmaceutical companies actively developing 22+ pipeline drugs. Advancements in precision medicine and personalized approaches are driving the market, enabling selective targeting of receptor subtypes and improving safety and efficacy.

GlobeNewswire Inc.

Featured Companies: ATAI CYBN HRMY MNMD
Reviva Announces Proposed Public Offering

Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced a proposed public offering of its common stock and warrants, with the proceeds to be used for research and development, working capital, and other general corporate purposes.

GlobeNewswire Inc.
Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight

The schizophrenia market is growing due to increased R&D activities, advancements in neurobiology and biomarkers, and ongoing clinical trials for more effective treatments. This has attracted significant investments and led to the development of innovative therapies, including novel antipsychotics and personalized medicine.

GlobeNewswire Inc.

Featured Companies: VNDA

Dividend data last updated 06/07/2025 00:02:38 UTC